211 related articles for article (PubMed ID: 9517367)
1. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
Mahmood I; Chamberlin N
Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
[TBL] [Abstract][Full Text] [Related]
2. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats.
Darweesh RS; Khamis TN; El-Elimat T
Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1871-1886. PubMed ID: 32424477
[TBL] [Abstract][Full Text] [Related]
3. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers.
Bedada SK; Appani R; Boga PK
Drug Res (Stuttg); 2017 Jan; 67(1):46-51. PubMed ID: 27776366
[TBL] [Abstract][Full Text] [Related]
4. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
[TBL] [Abstract][Full Text] [Related]
5. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects.
Bedada SK; Boga PK
Xenobiotica; 2017 Oct; 47(10):879-884. PubMed ID: 27690733
[TBL] [Abstract][Full Text] [Related]
6. A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax).
Mahmood I; Sahlroot JT
Biopharm Drug Dispos; 1997 Mar; 18(2):117-26. PubMed ID: 9099448
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
8. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation.
Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E
Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.
Sachdeo RC; Sachdeo SK; Walker SA; Kramer LD; Nayak RK; Doose DR
Epilepsia; 1996 Aug; 37(8):774-80. PubMed ID: 8764818
[TBL] [Abstract][Full Text] [Related]
10. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers.
Bedada SK; Nearati P
Phytother Res; 2015 May; 29(5):701-6. PubMed ID: 25624269
[TBL] [Abstract][Full Text] [Related]
11. A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats.
Chi YC; Lin SP; Hou YC
Toxicol Appl Pharmacol; 2012 Sep; 263(3):315-22. PubMed ID: 22813711
[TBL] [Abstract][Full Text] [Related]
12. The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation.
Ding JJ; Zhang YJ; Jiao Z; Wang Y
Acta Pharmacol Sin; 2012 Nov; 33(11):1431-40. PubMed ID: 23103621
[TBL] [Abstract][Full Text] [Related]
13. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
[TBL] [Abstract][Full Text] [Related]
15. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4.
Andreasen AH; Brøsen K; Damkier P
Epilepsia; 2007 Mar; 48(3):490-6. PubMed ID: 17346248
[TBL] [Abstract][Full Text] [Related]
16. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
[TBL] [Abstract][Full Text] [Related]
17. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine and carbamazepine-10,11-epoxide clearance measurements during continuous venovenous hemofiltration in a massive overdose.
Smollin CG; Petrie MS; Kearney T
Clin Toxicol (Phila); 2016 Jun; 54(5):424-7. PubMed ID: 26942940
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of carbamazepine from two slow-release preparations.
Reunanen M; Heinonen EH; Nyman L; Anttila M
Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339
[TBL] [Abstract][Full Text] [Related]
20. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
